PMID- 25433437
OWN - NLM
STAT- MEDLINE
DCOM- 20150924
LR  - 20181113
IS  - 1544-2241 (Electronic)
IS  - 1544-1873 (Linking)
VI  - 13
IP  - 1
DP  - 2015 Feb
TI  - Diabetes medications and bone.
PG  - 35-40
LID - 10.1007/s11914-014-0250-z [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a common chronic disease that may be 
      associated with an increased risk of fracture. Evidence that thiazolidinediones 
      (TZDs) increase fracture risk in women with T2DM has focused attention on the 
      skeletal effects of treatments for diabetes. Only scant, low-quality evidence is 
      available for non-TZD diabetes medications and bone health, but it suggests that 
      there are no clinically important effects.
FAU - Grey, Andrew
AU  - Grey A
AD  - Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New 
      Zealand, a.grey@auckland.ac.nz.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Osteoporos Rep
JT  - Current osteoporosis reports
JID - 101176492
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Bone and Bones/*drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Fractures, Bone/*chemically induced
MH  - Humans
MH  - Hypoglycemic Agents/*adverse effects
EDAT- 2014/12/01 06:00
MHDA- 2015/09/25 06:00
CRDT- 2014/12/01 06:00
PHST- 2014/12/01 06:00 [entrez]
PHST- 2014/12/01 06:00 [pubmed]
PHST- 2015/09/25 06:00 [medline]
AID - 10.1007/s11914-014-0250-z [doi]
PST - ppublish
SO  - Curr Osteoporos Rep. 2015 Feb;13(1):35-40. doi: 10.1007/s11914-014-0250-z.